NuCana plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NCNA research report →
About the company
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer.
- CEO
- Hugh Stephen Griffith
- IPO
- 2017
- Employees
- 20
- HQ
- Edinburgh, GB
Price Chart
- Market Cap
- $8.26M
- P/E
- -0.14
- P/S
- 0.00
- P/B
- 0.17
- EV/EBITDA
- 0.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -153.80%
- ROIC
- -90.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-29,353,000 · -54.51%
- EPS
- $-7.75 · -137.13%
- Op Income
- $-20,110,000
- FCF YoY
- 60.54%
- 52W High
- $25.60
- 52W Low
- $1.33
- 50D MA
- $1.97
- 200D MA
- $2.92
- Beta
- 2.24
- Avg Volume
- 45.27K
Get TickerSpark's AI analysis on NCNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | Levy Elliott M. | sell | 23,811,896 |
| Jun 19, 26 | Bloss Jeffrey D. | sell | 36,539,720 |
| Apr 15, 26 | Bruce Theresa Margaret Ms | other | 132,600,130 |
| Mar 18, 26 | Levy Elliott M. | other | 0 |
| Mar 18, 26 | Levy Elliott M. | other | 3 |
| Mar 18, 26 | Levy Elliott M. | other | 28,631,517 |
| Mar 18, 26 | Harrison David James | other | 77,520,679 |
| Mar 18, 26 | Mellish Martin C.B. | other | 0 |
| Mar 18, 26 | Mellish Martin C.B. | other | 7 |
| Mar 18, 26 | Mellish Martin C.B. | other | 42,362,799 |
Our NCNA coverage
Recent articles, reports, and earnings notes.
No research on NCNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NCNA report →Similar companies
Peers in the same neighborhood.